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Introduction 
Staphylococcus aureus remains one of the dominant pathogens in infective endocarditis 
(IE) causing 25% to 30% of all cases [1,2] including healthcare-associated IE which 
comprises about 30% of IE [3]. Most IE involves the aortic or mitral valves, with 
tricuspid valve involvement accounting for fewer than 10% of cases, often in association 
with injection drug use [1,4,5]. Prosthetic valve IE (PVE) and IE related to cardiovascular 
implantable electronic devices accounts for approximately one-third of all cases and is 
most commonly caused by coagulase-negative staphylococci [1,5].  
 However, S. aureus is equipped with microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMS): well defined adhesion molecules on the bacterial 
surface, able to promote adherence to cardiac endothelial cells. S. aureus can multiply 
and persist within cardiac cells, further promoting vegetation growth via activation of 
cytokines and thrombotic pathways [6]. Moreover in S. aureus -PVE, surface biofilm 
formation complicates eradication of the infection. S. aureus has been identified as an 
independent predictor of poor outcome in IE [7,8]. In this review an expert group from 
the International Society of Antimicrobial Chemotherapy (ISAC) will present recent data, 
evidence and personal experience on S. aureus IE. 
1. Recent evidence related to diagnosis of Staphylococcus aureus IE 
Despite advances in medical provision and interdisciplinary approaches to management, 
diagnostic latency of S. aureus IE remains a challenge. For both native valve IE and PVE 
diagnosis is still based on major and minor modified Duke criteria [7], entailing 
microbiology and other laboratory results, echocardiography and clinical appearances or 
features.  Liesman et al. recently published a review on laboratory diagnostics in IE, 
including the importance of culture and histological examination (if a microbial diagnosis 
has not been established at the time of surgery, including intraoperative valvular tissue), 
and molecular techniques [8]. Still in clinically suspected cases, traditional blood cultures 
(at least three sets, properly filled, ideally taken when patient is febrile and/or prior to 
commencing antimicrobial therapy) remain central to the diagnosis in most cases [4,9]. 
However, because the time required for blood culture results may delay diagnosis, novel 
molecular techniques for pathogen detection, identification and antimicrobial 
susceptibility may be useful in the future [10].  
 
 
S. aureus bacteraemia (SAB) in patients with prosthetic valves is a strong predictor of 
PVE [11]. The British Society for Antimicrobial Chemotherapy (BSAC) recommends 
echocardiography in all patients with SAB, ideally within the first week of treatment or 
within 24 hours if there is other evidence to suggest IE [9]. Transthoracic 
echocardiography (TTE) should be primarily performed in each patient with clinical 
suspicion of IE; the current European guidelines recommend transoesophageal 
echocardiography (TOE or TEE) in all patients with negative or non-conclusive TTE 
findings. An oscillating mass compatible with vegetation is not well visualized by TTE in 
PVE which has a relatively significant lower sensitivity than in native valve IE [12]. If a 
prosthetic heart valve or an intracardiac device, e.g., pacemaker, is present, a TOE should 
be performed as first choice. The only situation in which TTE is equal to TOE with 
respect to sensitivity of IE detection is right heart IE in patients with a good acoustic 
window [4]. Additionally novel imaging technologies such as white blood cell (WBC) 
single-photon emission CT (SPECT)/CT and 18F-FDG positron emission 
tomography (PET)/CT are generally recommended for complex clinical situations 
[4][13], but are not widely used for variety of reasons including cost, availability, and the 
experience of interpreting cardiologists.  
2. Recent evidence related to treatment of Staphylococcus aureus IE 
Guidelines for the treatment of IE were updated in 2015, both in America [14] , and in 
Europe [4]. Treatment of coagulase-negative staphylococci IE follows exactly the same 
principles, based on drug-susceptibility testing. The first-line backbone treatments are 
quite similar in both guidelines: intravenous anti-staphylococcal penicillin or cefazolin 
for methicillin-susceptible staphylococci IE, and intravenous vancomycin or daptomycin 
for methicillin-resistant staphylococci IE. Likewise, there is a general agreement that we 
should not systematically use aminoglycosides in the treatment of native valve 
staphylococcal IE, regardless of the susceptibility to methicillin, for the following 
reasons: i) the added value of aminoglycosides has never been proven in staphylococcal 
IE, even when evaluated in randomized studies [15]; and ii) conversely, recent data 
demonstrated their deleterious effect, even when administered only for a few days [16].  
For staphylococcal PVE, both guidelines recommend gentamicin during the first two 
weeks of treatment: two or three injections/day for Americans [14], and one or two 
injections/day for Europeans [4], in association with the backbone regimen (see above), 
and rifampin, that must be prolonged for at least 6 weeks. Of note, daptomycin is not 
supported for PVE by current guidelines despite available relevant data and experience 
with this agent [14]. Although the systematic use of gentamicin and rifampin in 
staphylococcal PVE is based on a low level of evidence, it could be justified by the 
requirement for highly bactericidal regimens to eradicate staphylococci on biofilms, 
taking into account that i) rifampin use has been associated with a lower risk of relapses 
in other foreign-device related staphylococcal infections (e.g., prosthetic joint infections) 
[17]; and ii) the early bactericidal effect of aminoglycosides may protect from the 
emergence of rifampin-resistant isolates, especially during the first days of treatment 
when bacterial inoculum is large, and the effect of the backbone regimen not fully 
established (especially with slowly bactericidal agent such as vancomycin).  
According to large epidemiological studies, methicillin-resistant S. aureus (MRSA) is 
more prevalent in PVE than in native valve IE. Early PVE (< 1 year from valve 
implantation) is more often caused by hospital-acquired MRSA strains, some with 
reduced susceptibility to vancomycin. Late PVE demonstrates a microbiological profile 
similar to community-acquired native IE [14,18]. Moreover, complications as valve 
abscess and embolization are more frequent in PVE. Patients with S. aureus PVE need 
individualized assessment for valve surgery [14,18] . The presence of a prosthetic valve 
is a major predictor of mortality in S. aureus IE. Valve dehiscence, re-operations and in-
hospital or 6-month mortality is further increased to 30-50% in patients with MRSA 
PVE. This difference may also reflect a higher Charlson comorbidity index score and 
older age in patients with PVE than native valve IE [18]. 
 
European guidelines promoted as an alternative the high dose combination of 
trimethoprim-sulfamethoxazole (TMP/SMX) (960 mg/day of trimethoprim, 4,800 
mg/day of sulfamethoxazole) for six weeks, in combination with clindamycin (1,800 
mg/day) for one week, in the treatment of native valve S. aureus IE, regardless of 
methicillin resistance. However, this should be discouraged in light of the two large 
randomized trials showing that TMP/SMX is inferior to vancomycin in the treatment of 
SAB. Likewise, European guidelines suggested cefotaxime as an alternative to cefazolin 
in penicillin-allergic patients with methicillin-susceptible staphylococci IE, but this is 
probably sub-optimal, in light of different in vitro, experimental, and cohort studies, 
suggesting that third-generation cephalosporins are significantly less active than cefazolin 
for methicillin-susceptible staphylococci [19].   
Despite these limitations, the updates of these guidelines are useful, enabling the 
optimization of staphylococcal IE treatment.  
 
3. Timing of vavlular surgery for Staphylococcus aureus IE 
The optimal time of valvular surgery in patients with S. aureus IE is still unclear [4]. S. 
aureus is the most common pathogen in right–sided valve IE (RVIE),  but surgical 
treatment is required (5-16%) much less often than for left-sided valve IE (LVIE) which 
generally could reach 50%. Cardiac surgery in RVIE is most often for prosthetic tricuspid 
valve S. aureus IE. For a damaged tricuspid valve in native IE, early valve surgery (EVS) 
within 7 days with valve repair is preferable to valve replacement, especially in 
intravenous drug-users (IVDUs) [20].  
Indications for surgery in LVIE includes heart failure, para-valvular complications, 
persistent infection and S. aureus PVE, the latter with level of evidence IIaC [4]. S. 
aureus PVE is often complicated (stroke, valve dehiscence) and might require EVS; 
however candidates and timing of surgery are not well defined. In a large international 
cohort of IE, S. aureus IE patients were treated more conservatively than non-S. aureus 
IE [OR 0.5, 95% CI (0.37-0.66)] [21]. Mortality was significantly lower in patients 
treated with both surgery and antibiotics compared with those treated only medically 
(33.7% vs 59%, p=0.001). However, a propensity score analysis, adjusted for survival 
bias, failed to demonstrate an overall significant survival benefit at one year of EVS in S. 
aureus PVE [21]. These results corroborate a previous study of S. aureus PVE in which 
>50% of the patients, especially the younger ones without systemic IE complications, 
were successfully treated only with antibiotics [22].  
Regarding the impact of MRSA on prognosis and the outcome of surgery, data are 
limited.  In one study, all patients with MSSA IE without indications for surgery 
survived, but one third of patients with MSSA IE who were operated upon indication 
died. Most MRSA patients were treated only with antibiotics (i.e., without surgery), and 
6-month mortality was higher among MRSA than MSSA IE cases [23].  
In conclusion, optimal timing of surgery in S. aureus IE should be individualized, taking 
into account the patients’ health status, IE complications, LVIE, PVE and evolution of 
the disease under antimicrobial therapy. Overall, surgery is recommended if benefits 
outweigh the operative risk. A tailored approach regarding timing of surgery, type of 
valve and surgical techniques is recommended [4]. 
 
4. New Antimicrobials and Their Role in MRSA IE 
 
Several new antimicrobials active against S. aureus from a variety of drug classes have 
been approved during the past decade. There are reports documenting successful off-label 
use of the new agents for bacteremia, endocarditis and other invasive infections (Table 1) 
[26,27, 29––45,28,46,47].  Further studies are needed to address the efficacy, and cost 
effectiveness of these new anti MRSA antibiotics in IE and other invasive infections. 
 
5. Special Considerations for IE in children     
 
Despite significant advances, IE in children continues to have a high mortality of up to 
10% although this compares favourably with the mortality in adults. While the basic 
principles of management of IE in the paediatric age group are broadly similar to those in 
adults, there are some significant differences. For example, TTE has a sensitivity of 80% 
in children and so unlike in adults, TOE is rarely indicated [46]. Echocardiogram should 
always be performed in children with SAB as a significant proportion of children have IE 
[47]. Staphylococci and streptococci are the major causes of IE in children. Staphylococci 
predominate in children without congenital heart disease. For example in a recent 
epidemiological investigation in Italy, S. aureus emerged as the leading cause of IE in 
children without predisposing cardiac ailments with an overwhelming majority (85.7%) 
of S. aureus isolates being MRSA [48].  
 
The incidence of IE in neonates is increasing as a result of improved diagnostic 
techniques and enhanced level of intervention such as the use of central venous catheters 
(CVCs). Septic emboli are common in neonates leading to signs of metastatic illness, 
such as seizures [49].   
 
β-lactamase stable penicillins are the mainstay of treatment of staphylococcal IE on 
native valves with the option of adding gentamicin for the first 3-5 days. For IE caused 
by MRSA, vancomycin remains the favoured agent with daptomycin as an alternative. 
High dose daptomycin (10 mg/kg once daily instead of the standard 6 mg/kg) is 
recommended in children ≤ 6 years to compensate for rapid clearance of this agent from 
the bloodstream [49] although an even higher dosage (12 mg/kg) has been used [50]. 
Combination of β-lactamase stable penicillins and vancomycin is an attractive option for 
staphylococcal infections until MRSA is ruled out particularly in units where prevalence 
of MRSA is high [46]. The recommended duration of treatment of staphylococcal IE is at 
least 4 weeks (6 weeks for MRSA and for PVE). As in adults, addition of rifampicin and 
gentamicin is recommended for PVE [49]. Experience with newer antibiotics is limited 
although linezolid has been successfully used in a neonate with IE caused by MRSA 
following failure of vancomycin therapy [51]. Dosing strategies for antibiotics may need 
to be individualized in order to optimize the pharmacokinetic/pharmacodynamics targets. 
Nichols and colleagues have published a useful commentary in relation to dose 
optimization in the paediatric age group in patients with IE [52].  
 
 
6. Antibiotic prophylaxis to prevent IE 
 
 
Recent reviews of endocarditis prophylaxis in the UK and the US [53–55] have 
challenged the practice of giving antibiotic prophylaxis to prevent IE in a range of 
invasive, minor procedures and highlighted the frequency of transient bacteraemia in 
everyday activities such as brushing teeth, the lack of association of many procedures 
with endocarditis and have questioned the efficacy of antibiotic prophylactic regimens.  
 
The perceived risk of IE among patients with cardiac conditions undergoing interventions 
is now felt to be minimal, and lower than the risks of severe adverse events, or indeed 
loss of life, from the adverse events and volume of prophylactic antibiotics used. For 
example, antibiotic prophylaxis against IE for dental procedures may lead to a greater 
number of deaths through fatal anaphylaxis than a strategy of no antibiotic prophylaxis, 
and is not cost effective. 
 
The following cardiac conditions are regarded as being at higher risk of endocarditis:  
acquired valvular heart disease with stenosis or regurgitation, valve replacement, 
structural congenital heart disease, previous IE, and hypertrophic cardiomyopathy. 
Emphasis is now placed on giving patients clear advice on oral hygiene and dental care, 
awareness of symptoms of IE and the importance of early medical intervention. 
 
Prophylaxis for IE remains a contentious issue. The UK National Institute for Health and 
Care Excellence (NICE) guideline published in 2008 and revised in 2015 does not 
recommend antibiotic prophylaxis even for patients at high risk of IE [56]. Prophylaxis 
with amoxicillin (clindamycin in penicillin allergic patients) is however recommended by 
the European Society of Cardiology guidelines for patients undergoing high-risk dental 
procedures [4]. Studies that were conducted following the restriction of antibiotic 
prophylaxis provided some evidence of increasing incidence of IE, but there was no 
microbiological information to support the view that oral streptococci were responsible 
for the rise in number of cases. Amoxicillin, which is the most commonly used 
prophylactic agent in the dental setting, is not active against a vast majority of isolates of 
S. aureus and consequently the debate on prophylaxis is mainly relevant to streptococcal 
infections. Prevention of S. aureus IE focuses mainly on healthcare-associated infections 
rather than those resulting from community dental procedures. 
 
 
Prevention of SAB is the key to prevent subsequent IE. Preventing healthcare-associated 
infection goes beyond the confines of antibiotic prophylaxis. Reduction in the incidence 
of CVC-related bacteraemia can be achieved by improving adherence to infection control 
practices such as hand hygiene and barrier precautions, full coverage of which is beyond 
the scope of this review. Guidelines for prevention of intravascular catheter related 
infections have been published [57], Borg et al. found that hospitals with competency 
programs in insertion of peripheral venous cannulae and CVCs have a lower prevalence 
of SAB. Root cause analysis of bacteraemia, hand hygiene audits, and antibiotic 
stewardship all contribute towards lowering of rates of bacteraemia [58].  
 
Vaccines against S. aureus have been investigated but failed to demonstrate efficacy in 
clinical trials. Vaccination is likely to be of benefit in select groups of patients at high 
risk of bacteraemia and its complications, for example, patients on chronic 
haemodialysis. Sustained immune response to the V710 vaccine was demonstrated in 
clinical trials [59]. However, a phase 3 trial of this vaccine did not demonstrate a 
reduction in the rate of S. aureus infections in the vaccine group. There was also higher 
mortality in the vaccine group compared to the control group in patients who developed 
S. aureus infection [60]. Much additional research is thus necessary to develop an 
effective vaccine and to determine the appropriate target population.        
 
 
7. Role of Panton Valentine leucocidin (PVL) and other toxins in Staphylococcus 
aureus IE incidence and outcome 
 
A range of S. aureus virulence factors have been implicated in IE. Most studies have 
proposed a relationship between IE and expression of secreted virulence factor 
superantigens in S. aureus. Superantigens include staphylococcal enterotoxins (SE), 
staphylococcal enterotoxins-like (SEl) molecules, and toxic shock syndrome toxin-1 
(TSST-1 encoded by tstH). While three of these superantigens (TSST-1, SEB and SEC) 
are associated with toxic shock syndrome, others may primarily contribute to local effects 
such as vegetation formation in IE. A prospective study showed that MSSA CC30 IE 
isolates were significantly more likely to contain genes for TSST-1 as well as some 
staphylococcal enterotoxins (sea, sed, see) and SEl molecules (sei) [61]. The frequency 
of sed was significantly higher in MRSA compared to MSSA IE isolates in a small 
retrospective study, notwithstanding the absence of association with mortality [62]. A 
more recent experimental study has emphasised the role in IE of an operon comprising 
one SE gene (seg) and SE-like genes (selo, selm, sei, selu, seln, and seg) known as the 
enterotoxin gene cluster (egc) that is highly prevalent in S. aureus [63]. Stach et al. 
showed that while TSST-1 contributes to both IE and sepsis, the effect of egc 
superantigens is limited to vegetation formation in IE. Population-based epidemiological 
studies to further support the role of S. aureus superantigens in IE are not available. 
 
Other studies have focused on the role of regulatory networks such as the quorum-
sensing operon agr (accessory gene regulator) implicated in induction of expression of 
virulence factors. In a rabbit model of IE, infection persistence after treatment with 
vancomycin correlated with early agr activation [64]. However, other experimental 
studies suggest that agr is not a key regulator of virulence factor gene expression and 
instead attributed this role to gene regulator MgrA [65]. Epidemiological data are 
required to confirm the importance of these two global regulatory elements in 
establishment and progression of IE as well as failure of vancomycin therapy.  
Evidence to support the role of PVL in pathogenesis of S. aureus IE is limited to small 
studies and case series/reports (Table 2).  
 
 
 
 
 
 
 
 
 
  
Table 1: Summary of some novel antibiotics with potential role in MRSA Infective Endocarditis   
 
Agents Comments including experience in infective endocarditis (IE) 
Cephalosporins 
 
Ceftaroline and Ceftobiprole; both active against 
MRSA and are bactericidal with favorable safety 
profiles. Both are currently only approved 
[Ceftaroline (FDA) and ceftobiprole (Europe)] for 
acute bacterial skin and skin structure infections 
(ABSSSI) and community acquired pneumonia. 
There have been case reports and series documenting the successful use of ceftaroline for IE [24], including a successful treatment of vancomycin-
intermediate and daptomycin-non-susceptible S. aureus [25]. Ceftaroline was reported to be noninferior to vancomycin the treatment of MRSA 
bacteremia in a retrospective study in Michigan [26] , and was studied in a retrospective multicenter cohort of 211 MRSA bacteremia patients [27]. An 
observational study from France of left-sided IE treated with ceftaroline either as monotherapy or in combination with another agent reported a cure 
in 5 of 8 patients [28]. Several other case reports are published on successful use of ceftaroline in combination with daptomycin for MRSA, VISA, and 
daptomycin non susceptible Staphylococcus aureus IE [25,29,30] but this approach requires further study. To our knowledge there are no published 
reports of ceftobiprole being used for IE therapy. 
Lipoglycopeptides 
 
Over the last decade three new lipoglycopeptides 
were approved by the FDA for ABSSSI; Telavancin , 
dalbavancin and oritavancin. The long half-lives 
and extended dosing regimen of the latter two 
make them especially appealing for future use in 
MRSA IE. However, the long half-lives may be an 
issue for empirical therapy. 
Telavancin is a bactericidal once-daily agent that achieved a similar cure rate compared with standard therapy in SAB in a small, randomized trial [31]. 
In a retrospective study of 14 patients with refractory MRSA bacteremia and IE, the response rate to telavancin was similar to daptomycin or 
vancomycin; 8 subjects survived to hospital discharge, 5 of whom had IE. The 6 who did not survive all had IE, and 5 of these were deemed not to be 
surgical candidates [32]. Telavancin is relatively contraindicated in patients with renal dysfunction as it is associated with increased mortality in this 
population.   
 
Dalbavancin is a lipoglycopeptide with once weekly dosing. In a phase 2 study catheter-related MSSA and MRSA bloodstream infections, dalbavancin 
had a higher success rate than vancomycin [33]. In a recently published paper, the clinical outcomes and safety of dalbavancin as primary and 
sequential treatment of Gram-positive bacteremia with IE were evaluated in a single center.  Clinical success with dalbavancin was high (92.6%) but in 
the majority of patients (24/27) dalbavancin was only used after clearance of bacteria from bloodstream [34]. Another recent retrospective study 
from Spain assessing dalbavancin therapy for a variety of invasive infections, including bacteremia, demonstrated clinical success in 84.1% of cases 
and also a reduction in number of hospitalization days and cost [35]. Despite these encouraging results, there was a recent case report documenting 
failure of therapy in a pregnant patient with MRSA IE after 4 weeks of dalbavancin [36]. The treatment failed due to reinfection with VISA, perhaps 
due to inadequate dalbavancin exposure. Another reason for a cautious approach to using this drug for IE is that it was not bactericidal in a rabbit 
model of IE [37].   
 
Oritavancin is another lipoglycopeptide approved for ABSSSI with a very long half-life, ranging from 245 to 393h. In a recent case series of 17 patients 
treated with oritavancin for invasive, complicated Gram-positive infections, including 2 patients with MRSA pneumonia, all improved, although 4 had 
an adverse reaction [38]. In another case series, 7 of 10 patients with invasive bacterial infections treated with oritavancin were cured although only 
one of these patients had a MRSA infection [39]. A notable recent report documented success of therapy with oritavancin for a case of refractory 
MRSA IE [40]. Oritavancin thus may be useful for MRSA IE although more data are needed before it is recommended.  
Oxazolidinone 
 
Tedizolid is the newest oxazolidinone antibiotic 
approved for ABSSSI. As for linezolid, it is 
considered a bacteriostatic, rather than a 
bacteriocidal drug and is not likely to become a 
first-line agent for bacteremia or IE. However, it 
has a high oral bioavailability and only requires 
once daily dosing [41]. 
Currently, there are no published case reports of its use in the therapy of IE; however, in a 2015 study of a rabbit model of S. aureus IE compared 
tedizolid, daptomycin, and vancomycin. Tedizolid had modest bactericidal in vivo activity but was less active than the other two drugs [42]. Also, the 
combination of tedizolid and daptomycin in simulated endocardial vegetations suggested an antagonistic relationship that impeded antimicrobial 
activity [43]. Additional investigation is thus needed before tedizolid is used to treat IE. 
Other novel drugs 
 
There are several new drugs that may be feasible 
options for MRSA IE treatment in the future, 
including delafloxacin and iclaprim.  
 
 
Delafloxacin, a fluoroquinolone approved by the FDA in 2017 for the treatment of ABSSSI with activity against MRSA, demonstrates lower MICs 
compared with other fluoroquinolones, a higher barrier to resistance, and good activity against biofilms [44]. However, there are no current studies 
or reports regarding Delafloxacin use in IE or bacteremia.  
 
Iclaprim is a diaminopyrimadine that inhibits bacterial dihydrofolate reductase. The drug completed Phase 3 trials for ABSSSI that demonstrated it 
was non-inferior to vancomycin and had a favorable safety profile [45]. While iclaprim is still new to the field, future exploration is warranted for 
indications for invasive infections. 
 
Abbreviations:  ABSSSI, acute bacterial skin and skin structure infection; FDA, U.S. Food and Drug Administration; IE, infective endocarditis; 
MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; SAB, Staphylococcus aureus 
bacteremia; VISA, vancomycin-intermediate Staphylococcus aureus.  
 
 
Table 2: Evidence to support the role of Panton-Valentine leucocidin (PVL) in pathogenesis of S. aureus-related IE  
Background Risk factors  Reference   
IE related to PVL+ CA-MRSA was initially 
reported in previously five healthy patients  
Following development of 
furunculosis 
[66] 
PVL+ MRSA IE, five cases caused by the 
USA300 CA-MRSA clone, and two cases of HA-
MRSA 
Intravenous drug use [67] 
In a cohort of 131 HIV-infected patients with 
S. aureus bacteraemia, patients with USA300 
PVL+ CA-MRSA infections had significantly 
greater odds of IE (OR = 2.73)  
HIV patients with USA300 
PVL+ CA-MRSA infections 
[68] 
A case of IE related to the PVL+ CA-MRSA 
ST93 (Queensland) strain  
Intravenous drug use in 
one out of two cases; the 
second case had no 
reported risk factors 
[69] 
The first and only case of IE relating to PVL+ 
CA-MSSA (to the best of our knowledge),  
reported in a 76-year old man in Japan who 
was treated with ceftriaxone and gentamicin 
followed by cardiac surgery  
 
None known, apart from 
age 
[70] 
Abbreviations: CA-MSSA, community-associated methicillin-susceptible Staphylococcus aureus; CA-MRSA, community-associated methicillin-
resistant Staphylococcus aureus; HA-MRSA, healthcare-associated methicillin-resistant Staphylococcus aureus; HIV, human immunodeficiency 
virus; IE, infective endocarditis; OR, odds ratio; PVL+, Panton-Valentine leucocidin positive.  
 
 
Conclusion  
 
S. aureus IE is a common clinical infection with a high mortality. In order to prevent 
infection and decrease mortality from S. aureus IE, further research is need to define its 
molecular epidemiology, importance of bacterial toxins and other virulence factors, 
modifiable host risk factors, optimal choice of empiric and definitive antimicrobial 
therapies, and the timing and indications for valvular surgery. While awaiting these 
research, native valve staphylococcal IE should be treated with a 4-6 week-course of a 
single agent, intravenous anti-staphylococcal penicillin or cefazolin for methicillin-
susceptible staphylococci, and vancomycin or daptomycin for methicillin-resistant 
staphylococci. For prosthetic valve staphylococcal IE, this must be reinforced with the 
adjunction of gentamicin during the first two weeks, and rifampin during the whole 
duration (i.e. 6 weeks). Timing of surgery in S. aureus IE should be individualized. 
Further studies are also needed regarding the use of ceftobiprole and ceftaroline as single 
agents in the management IE. 
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